Efficacy of Combination of Intravenous Cyclosporin A and Steroid Therapy versus Prolonged Intravenous Steroid Therapy Alone in Patients with Severe Ulcerative Colitis Refractory to Initial Intravenous Steroid Therapy.
- Author:
Goh Eun CHUNG
1
;
Jae Hee CHEON
;
Jong Yeul LEE
;
Byong Duk YE
;
Sang Gyun KIM
;
Joo Sung KIM
;
Hyun Chae JUNG
;
In Sung SONG
Author Information
1. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea. jooskim@snu.ac.kr
- Publication Type:Original Article ; English Abstract
- Keywords:
Ulcerative colitis;
Corticosteroid;
Cyclosporin A
- MeSH:
Aged;
Aged, 80 and over;
Antibodies, Monoclonal;
Carcinoma, Squamous Cell/*metabolism/pathology;
Cyclin D1/immunology/*metabolism;
Cyclin-Dependent Kinase Inhibitor p16/immunology/*metabolism;
Esophageal Neoplasms/*metabolism/pathology;
Esophagus/*abnormalities/metabolism/pathology;
Female;
G1 Phase;
Humans;
Immunohistochemistry;
Male;
Middle Aged;
Tumor Markers, Biological/metabolism;
Tumor Suppressor Protein p53/immunology/*metabolism
- From:The Korean Journal of Gastroenterology
2006;48(4):263-268
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: Maximal duration of intravenous (IV) corticosteroid (CS) treatment and efficacy of cyclosporin A (CsA) have not been clarified for patients with severe ulcerative colitis. We aimed to evaluate and compare the effectiveness of CS and CsA combination therapy with prolonged CS therapy alone in patients with severe UC refractory to initial CS therapy. METHODS: We retrospectively reviewed the medical records of 84 episodes of severe UC in 59 patients between April 1999 and May 2005. RESULTS: Among 84 episodes with IV CS therapy, 45 (53.6%) experienced an early response, while 39 (46.4%) did not respond within 2 weeks. The remaining 36 episodes excluding 3 which underwent colectomy were assigned to either combination therapy of IV CS and CsA or prolonged IV CS treatment alone for additional 2 weeks. Twelve of 16 episodes (75.0%) responded to therapy with combinations of IV CsA and CS, and 16 of 20 episodes (80.0%) to prolonged IV CS treatment alone. There was no statistical difference in response and colectomy rate after 4 weeks between CsA-use group and CsA-non-use group (p=1.00). CONCLUSIONS: These results suggest that CS and CsA combination has no additional benefit over prolonged CS therapy alone in terms of short-term response and that CS can be safely prolonged even after the first 14 days of treatment for severe UC.
